EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Real‐world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study

Elisa Lucchini iD, Nicola Vianelli, Ugo Consoli, Giuseppe Carli, Valentina Carrai, Monica Carpenedo iD, Valerio De Stefano iD, Gianluca Gaidano, Francesca Palandri iD, Giuseppe Auteri, Elena Rossi, Andrea Patriarca und 22 weitere

British Journal of Haematology · 2025-12 · 207 (6) · 2529-2538

DOI: 10.1111/bjh.70069 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, online erschienen am 25.08.2025. Verfasst von Elisa Lucchini und 33 weiteren Autor:innen. Beteiligte Einrichtung: UCO Ematologia, Azienda Sanitaria Universitaria Giuliano-Isontina, Trieste, Italy. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Oxazines, Morpholines, Pyridines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Grifols.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The efficacy and safety of fostamatinib in adult patients with persistent/chronic immune thrombocytopenia (p/c ITP) were demonstrated in the FIT‐1/FIT‐2 trials. This retrospective, multicentre observational study evaluated real‐world outcomes in consecutive p/c ITP patients treated with fostamatinib in Italy. The primary end‐point, serving as a surrogate for both efficacy and safety, was the proportion of patients receiving fostamatinib for at least 6 months. Ninety‐five patients were enrolled across 20 Italian centres, 59% female, median age 64 years (range 21–86). The median time from ITP diagnosis to fostamatinib initiation was 7.7 years; the median number of prior therapies was 4, including 54% of patients who received more than one thrombopoietin receptor agonist (TPO‐RA) and 23% who underwent splenectomy. The overall response rate was 73%, with 32% complete responses. Most patients (74%) achieved a response within the first month. Concerning the primary end‐point, 45% of patients received fostamatinib for 6 months; the median treatment duration was 7.3 months. The main cause of discontinuation was treatment failure (43%). Fifty‐nine adverse events were reported in 38 patients, mostly grade 1–2, leading to fostamatinib discontinuation in 8% of patients. This real‐world data confirm fostamatinib as an effective and safe option in relapsed/refractory ITP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombocytopenic, IdiopathicOxazinesMorpholinesPyridinesHumansFemaleMiddle AgedMaleAdultAgedAged, 80 and overRetrospective StudiesItalyAminopyridinesPyrimidinesYoung AdultTreatment Outcome

Stichwörter der Autor:innen

ITPfostamatinibreal world

Substanzen

fostamatinibAminopyridinesPyrimidinesOxazinesMorpholinesPyridines

Autor:innen und Institutionen

  • UCO Ematologia, Azienda Sanitaria Universitaria Giuliano-Isontina, Trieste, Italy.
  • Hematology Institute 'Lorenzo & Ariosto Seràgnoli' IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola, Bologna, Italy.
  • UOC Ematologia, ARNAS Garibaldi, Catania, Italy.
  • Hematology Unit, Ospedale San Bortolo, ULSS8 Berica, Vicenza, Italy.
  • Azienda Ospedaliero Universitaria Careggi, SOD Ematologia, Florence, Italy.
  • Department of Hematology, Oncology and Molecular Medicine, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

ORCID-Profile: Elisa Lucchini, Monica Carpenedo, Valerio De Stefano, Francesca Palandri

Förderung

  • Grifols

Zitieren

APA

Lucchini, E., Vianelli, N., Consoli, U., Carli, G., Carrai, V., Carpenedo, M., De Stefano, V., Gaidano, G., Palandri, F., Auteri, G., Rossi, E., Patriarca, A., Innao, V., Marchesini, G., Ballerini, M., Rossetti, M. C., Mosini, G., Sciancalepore, P., Agnelli Giacchello, J., …, & Zaja, F. (2025). Real‐world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study. British Journal of Haematology, 207(6), 2529-2538. https://doi.org/10.1111/bjh.70069

Vancouver

Lucchini E, Vianelli N, Consoli U, Carli G, Carrai V, Carpenedo M, et al. Real‐world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study. British Journal of Haematology. 2025;207(6):2529-2538. doi:10.1111/bjh.70069

BibTeX
@article{Lucchini2025,
  author = {Lucchini, Elisa and Vianelli, Nicola and Consoli, Ugo and Carli, Giuseppe and Carrai, Valentina and Carpenedo, Monica and De Stefano, Valerio and Gaidano, Gianluca and Palandri, Francesca and Auteri, Giuseppe and Rossi, Elena and Patriarca, Andrea and Innao, Vanessa and Marchesini, Gessica and Ballerini, Mario and Rossetti, Maria Chiara and Mosini, Giulia and Sciancalepore, Patrizia and Agnelli Giacchello, Jacopo and Musto, Pellegrino and Rivolti, Elena and Soverini, Giulia and Borchiellini, Alessandra and Clissa, Cristina and Pane, Fabrizio and Galimberti, Sara and Pavone, Vincenzo and Poloni, Antonella and Buccisano, Francesco and Musso, Maurizio and Fazi, Paola and Paoloni, Francesca and Gorreo Renzulli, Livia and Zaja, Francesco},
  title = {Real‐world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study},
  journal = {British Journal of Haematology},
  year = {2025},
  volume = {207},
  number = {6},
  pages = {2529--2538},
  doi = {10.1111/bjh.70069}
}
Kostenlos starten →